CEO Spotlight: FendX Technologies
This is a paid advertisement on behalf of FendX Technologies Inc. Today, we have FendX Technologies CEO Carolyn Myers with us and we are excited to learn more about her…
Lexaria’s DehydraTECH-Nicotine Faster than ZYN and on!
KELOWNA, BC / ACCESSWIRE / August 9, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to report results from…
FendX Technologies: A Deep Dive
This is a paid message on behalf of FendX Technologies Inc. Although the COVID pandemic created numerous challenges for the global economy, it facilitated the advancement of several industries. From…
Lexaria’s Plans to Study Weight Loss and Diabetes Control in a Human Clinical Study with DehydraTECH-CBD
KELOWNA, BC / ACCESSWIRE / August 2, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to report its intention to…
Lexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine Study
KELOWNA, BC / ACCESSWIRE / July 28, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces it has incorporated a new wholly-owned…
Lexaria Biotech: An Undervalued Growth Opportunity
Last month, we highlighted Lexaria Bioscience Corp. (Nasdaq: LEXX) as a biotech company that was trading at a discount and wanted to issue an update after it made several important…
Lexaria Receives New Patents
KELOWNA, BC / ACCESSWIRE / June 20, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces that it has received notifications of…
Lexaria Discovers that DehydraTECH-CBD Treatment in Hypertension Study HYPER-H21-4 Resulted in Reduction in Pro-Inflammatory Biomarkers
KELOWNA, BC / ACCESSWIRE / May 23, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to announce additional findings from…
Lexaria’s Human Clinical Nicotine Study Completes Dosing as Planned
KELOWNA, BC / ACCESSWIRE / May 8, 2023 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces that dosing of the targeted 36…
Lexaria Bioscience Continues To Execute
Last week, Lexaria Bioscience Corp. (Nasdaq: LEXX) reported two major developments that our readers should be aware of. The more significant announcement was Lexaria awarding a contract for clinical research…
